Jump to page content
For its very first edition, held at the innovative biomedical Campus Berlin-Buch, the DECHEMA colloquium will focus on protein modifications and their significant role in the development of new forms of therapy and diagnosis.

We are proud to announce that Alfred Goldberg from the Harvard Medical School will give a keynote lecture on proteasome regulation, with a focus on connecting our understanding of mechanisms to disease therapies. Further fascinating presentations will address the role of protein modifications in signal transduction, protein stability, their usage in Captured Compound Mass Spectrometry, and innovative technologies for protein labeling, glycooptimisation and multimerization.

A poster session and get-together will close the event and provide plenty of time for networking. The event aims to bring together scientists from academic research and biotech companies.

Prof. Goldberg’s laboratory has long been investigating the pathways for protein degradation in animal and bacterial cells and first described both the 26S proteasome, which degrades ubiquitinated proteins and the ATP-dependent proteases that catalyze protein turnover in bacteria. They also initiated the development of the proteasome inhibitors widely used in the treatment of multiple myeloma and as research tools. Their recent discoveries about proteasome activation by phosphorylation illustrate the possibility of novel treatments for proteotoxic disease (e.g. Alzheimer’s disease). Also, they have recently identified a novel targets and inhibitors for drugs to treat the essential ATP-dependent proteolytic enzymes, ClpC1P1P2 and ClpXP1P2.


28 November 2016
2 - 7 pm


Campus Berlin-Buch
Max Delbrück Communications Center (MDC.C)
C83, Axon 2
Robert-Rössle-Straße 10
13125 Berlin


The meeting is free of charge. You can register online on the DECHEMA website.